Craig R. Feinberg

Array ( [id] => 19425270 [patent_doc_number] => 12084673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Vectors for the treatment of Friedreich's ataxia [patent_app_type] => utility [patent_app_number] => 16/757263 [patent_app_country] => US [patent_app_date] => 2018-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10992 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18352559 [patent_doc_number] => 20230140670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/651911 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029954 [patent_doc_number] => 11091760 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Recombinant virus products and methods for inhibition of expression of myotilin [patent_app_type] => utility [patent_app_number] => 16/144432 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 19 [patent_no_of_words] => 10570 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790785 [patent_doc_number] => 20190008931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/136926 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790787 [patent_doc_number] => 20190008932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/137028 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790789 [patent_doc_number] => 20190008933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/137049 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15606231 [patent_doc_number] => 10584165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Methods and compositions for delivering mRNA coded antibodies [patent_app_type] => utility [patent_app_number] => 16/129412 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18020 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238633 [patent_doc_number] => 20200255867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => DOUBLE SELECTION HDR CRISPR-BASED EDITING [patent_app_type] => utility [patent_app_number] => 16/643251 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618719 [patent_doc_number] => 20180360911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ATHEROSCLEROSIS INHIBITION VIA MODULATION OF MONOCYTE-MACROPHAGE PHENOTYPE USING APO A-I MILANO GENE TRANSFER [patent_app_type] => utility [patent_app_number] => 16/114635 [patent_app_country] => US [patent_app_date] => 2018-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16114635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982421 [patent_doc_number] => 20190060368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles And Uses Thereof In Autoimmune Diseases [patent_app_type] => utility [patent_app_number] => 16/112282 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14653427 [patent_doc_number] => 20190233842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 16/107929 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16107929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586653 [patent_doc_number] => 20180344875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO [patent_app_type] => utility [patent_app_number] => 16/101327 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16101327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13899057 [patent_doc_number] => 20190038733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/100120 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16518645 [patent_doc_number] => 10869847 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Ceramide composition and method of use [patent_app_type] => utility [patent_app_number] => 16/046246 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 20 [patent_no_of_words] => 8057 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567431 [patent_doc_number] => 20190211322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/042004 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13507847 [patent_doc_number] => 20180305466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => METHODS FOR PRODUCING FABS AND BI-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/029196 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957899 [patent_doc_number] => 20190055293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF) [patent_app_type] => utility [patent_app_number] => 16/022410 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16022410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17028587 [patent_doc_number] => 11090385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Early cancer detection and enhanced immunotherapy [patent_app_type] => utility [patent_app_number] => 16/004401 [patent_app_country] => US [patent_app_date] => 2018-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 31582 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16004401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16445102 [patent_doc_number] => 10837018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use [patent_app_type] => utility [patent_app_number] => 15/980428 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 31 [patent_no_of_words] => 14893 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19164758 [patent_doc_number] => 11980640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Bicistronic chimeric antigen receptors and their uses [patent_app_type] => utility [patent_app_number] => 16/613187 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 68 [patent_no_of_words] => 25843 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613187 [rel_patent_id] =>[rel_patent_doc_number] =>)